Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 19/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2893114 | 0.93 | AVPR1B (0.83) | AVPR1BCYP3A4 | |
| SCHEMBL2891326 | 0.92 | AVPR1B (0.87) | AVPR1BCYP3A4LMNAMAPTRECQL | |
| SCHEMBL2885043 | 0.91 | AVPR1B (0.86) | AVPR1BCYP3A4LMNAMAPTRECQL | |
| SCHEMBL2890581 | 0.91 | AVPR1B (1.00) | AVPR1BCYP3A4LMNAMAPTRECQL | |
| SCHEMBL2884615 | 0.90 | AVPR1B (0.83) | AVPR1BCYP3A4LMNAMAPTRECQL | |
| SCHEMBL15101605 | 0.88 | AVPR1B (0.64) | AVPR1BCYP3A4LMNAMAPTRECQL | |
| SCHEMBL2892483 | 0.87 | AVPR1B (0.79) | AVPR1BCYP3A4LMNAMAPTRECQL | |
| SCHEMBL2890762 | 0.87 | AVPR1B (0.76) | AVPR1BCYP3A4LMNA | |
| SCHEMBL2890612 | 0.86 | AVPR1B (1.00) | AVPR1BCYP3A4LMNAMAPTRECQL | |
| SCHEMBL2889092 | 0.86 | AVPR1B (0.82) | AVPR1BCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486931-B2 | Substituted oxindole compounds | ABBOTT GMBH & CO. KG (DE) | 2013-07-16 | — | — | US | disclosed |
| US-20100286165-A1 | SUBSTITUTED OXINDOLE COMPOUNDS | ABBOTT GMBH & CO. KG (DE) | 2010-11-11 | — | — | US | disclosed |
| WO-2008107399-A1 | SUBSTITUTED OXINDOLE COMPOUNDS | ABBOTT GMBH & CO. KG (DE) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286165-A1 | SUBSTITUTED OXINDOLE COMPOUNDS | OXTR, AVPR2, AVPR1A | AVPR1B 4/4885CYP3A4 907/4885LMNA 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.